30-day mortality after systemic anticancer treatment for breast and lung cancer in Engl... - 0 views
-
Our data also suggest that 30-day mortality might be higher than previously estimated by several clinical trials.9, 10 The 30-day mortality rate after SACT with curative intent for NSCLC reported here is high at 3% compared with published trial data for the standard treatments, which suggested that 0·8% of patients died from treatment-induced toxicity when chemotherapy was given as adjuvant treatment alongside surgery
-
findings of clinical trials in selected age cohorts cannot readily be generalised to all patients
-
Population study from England finds significant increase in mortality in first 30 days of chemotherapy in breast and lung cancer treatment. The previously published trial dat was 0.8%; this study was as high as 3%. This cast doubt as to the inference of the risk from clinical trials to the general population.